FORT COLLINS, Colo. & MADISON, Wis.--(BUSINESS WIRE)--Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, announced today that it has received two grants totaling $488,958 through the United States government’s Qualifying Therapeutic Discovery Project Program. The grants were awarded to Inviragen for the Company’s ongoing programs to develop vaccines against dengue and chikungunya viruses. Inviragen is currently testing its dengue vaccine, DENVax, in two Phase 1 human clinical trials, while the Company’s experimental chikungunya vaccine is undergoing preclinical testing.
